ZEB2 and colorectal carcinoma: Therefore, we investigated the impact of ZEB2 on chemoresistance to cytotoxic agents used in FOLFOX regimen (5‐FU and oxaliplatin) using a previously established CRC cell line with DOX‐inducible expression of ZEB2 (DLD1‐ZEB2 cells) [21].